Literature DB >> 3882391

Diuretics. Clinical pharmacology and therapeutic use (Part I).

A Lant.   

Abstract

25 years have elapsed since the introduction of the first effective oral diuretic, chlorothiazide. Diuretics are now amongst the most widely prescribed drugs in clinical practice worldwide. Availability of these drugs has not only brought therapeutic benefit to countless numbers of patients but it has at the same time provided valuable research tools with which to investigate the functional behaviour of the kidney and other electrolyte-transporting tissues. Despite many remaining gaps in our knowledge of the biochemical processes involved in diuretic drug action, available compounds can be divided into 5 groups on the basis of their preferential effects on different segments of the nephron involved in tubular reabsorption of sodium chloride and water. Firstly, there is heterogeneous group of chemicals that share the common property of powerful, short-lived diuretic effects that are complete within 4 to 6 hours. These agents act on the thick ascending limb of Henle's loop and are known as 'high ceiling' or 'loop' diuretics. The second group are the benzothiadiazines and their many related heterocyclic variants, all of which localise their effects to the early portion of the distal tubule. The third group comprises the potassium-sparing diuretics which act exclusively on the Na+-K+/H+ exchange mechanisms in the late distal tubule and cortical collecting duct. The action of drugs in groups 2 and 3 is prolonged to between 12 and 24 hours. The fourth group consists of diuretics that are chemically related to ethacrynic acid but have the unusual property of combining within the same molecule the property of saluresis and uricosuria. These compounds have actions, to different individual extents, in the proximal tubule, thick ascending limb, and early distal tubule and are known as 'polyvalent' diuretics. Finally, there is a mixed group of weak or adjunctive diuretics which includes the vasodilator xanthines such as aminophylline, and the osmotically active compounds such as mannitol. Available evidence on the molecular mechanisms of action of diuretics in each group is reviewed. The haemodynamic, humoral and physical factors involved in control of electrolyte and fluid handling by the kidney in normal conditions and pathological states are discussed in relation to rational choices of different diuretics in the treatment of various oedematous and non-oedematous conditions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3882391     DOI: 10.2165/00003495-198529010-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  221 in total

Review 1.  Salt in hypertension and the effects of diuretics.

Authors:  E D Freis
Journal:  Annu Rev Pharmacol Toxicol       Date:  1979       Impact factor: 13.820

2.  Renin release by diuretics.

Authors:  L Nascimento; J M Ayala; R A Baquero; M Martinez-Maldonado
Journal:  J Pharmacol Exp Ther       Date:  1979-03       Impact factor: 4.030

Review 3.  Control of NaCl transport in the thick ascending limb.

Authors:  S C Hebert; T E Andreoli
Journal:  Am J Physiol       Date:  1984-06

4.  Properties of the basolateral membrane of the cortical thick ascending limb of Henle's loop of rabbit kidney. A model for secondary active chloride transport.

Authors:  R Greger; E Schlatter
Journal:  Pflugers Arch       Date:  1983-03       Impact factor: 3.657

5.  Localization of the site of action of oral diuretics in the human kidney.

Authors:  A F Lant; W I Baba; G M Wilson
Journal:  Clin Sci       Date:  1967-08       Impact factor: 6.124

Review 6.  Neurogenic regulation of renal tubular sodium reabsorption.

Authors:  G F DiBona
Journal:  Am J Physiol       Date:  1977-08

7.  Bumetanide: potent new "loop" diuretic.

Authors:  M J Asbury; P B Gatenby; S O'Sullivan; E Bourke
Journal:  Br Med J       Date:  1972-01-22

8.  Furosemide kinetics in renal failure.

Authors:  W J Tilstone; A Fine
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

9.  Effect of probenecid on the dose-response relationship of bumetanide at steady state.

Authors:  H S Lau; L J Shih; D E Smith
Journal:  J Pharmacol Exp Ther       Date:  1983-10       Impact factor: 4.030

10.  Effect of furosemide on calcium and magnesium transport in the rat nephron.

Authors:  G A Quamme
Journal:  Am J Physiol       Date:  1981-10
View more
  21 in total

Review 1.  Thiazides in the 1990s.

Authors:  M Orme
Journal:  BMJ       Date:  1990-06-30

Review 2.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 3.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 4.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

5.  Hypertension. Current therapeutic practice reviewed.

Authors:  B N Prichard
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 6.  Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

Review 7.  Diuretic drugs. Progress in clinical pharmacology.

Authors:  A Lant
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Development of acute tolerance to bumetanide: constant-rate infusion studies.

Authors:  J A Cook; D E Smith
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

9.  Amiloride disposition in geriatric patients: importance of renal function.

Authors:  A Somogyi; D Hewson; M Muirhead; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

10.  The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man.

Authors:  J J Dixey; F H Noormohamed; A F Lant; D A Brewerton
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.